Pre-Earnings Calithera Biosciences Inc. Analyst Report Issued by BrokerBank Securities, Inc.
NEW YORK, March 26, 2015 /PRNewswire/ -- Calithera Biosciences Inc. (NASDAQ: CALA) based in San Francisco, CA a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer will be reporting fourth quarter and year-end earnings this morning. Anticipation of this release has driven the recent investor interest in the shares of Calithera. Rollercoaster – like activity was observed for the past 4 trading days.
The company began clinical studies on its lead drug at the beginning of 2015; a press release accompanied by a nearly 350% price appreciation over a period of 5 days. Expectations are similar from investors, however, as with any clinical – stage company the large rewards come with definite risk. Earnings for this quarter and year – end should not have a major impact on the share price given no news or updates on the ongoing clinical studies. Results for those are expected in mid – 2015.
For a more detailed research report with analyst comments and recommendation on Calithera Biosciences Inc. please follow the link. There is no cost obligation required to view analyst brief:
http://bit.ly/-CALA-AnalystReport
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form. A full disclaimer can be found by viewing the full analyst report.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Robert Borowski, CFA Candidate. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Share this article